GBE1 knockdown can promote the secretion of CCL5 and CXCL10, and the recruitment of CD8+ T lymphocytes into the tumor microenvironment, suggesting that GBE1 may be an important target to inhibit the progression of LUAD tumor through immunotherapy (Li et al., 2019). Here, CD8A is linked to neoplasm.